{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:28:23Z","timestamp":1791912503646,"version":"4.3.4"},"reference-count":23,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2024,6,10]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-\u03b1) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of pegIFN-\u03b1 on T and natural killer (NK) cell responses in NUC-suppressed patients to identify cellular and\/or serological parameters to predict better T cell-restoring effect and better control of infection in response to pegIFN-\u03b1 for a tailored application of IFN-\u03b1 add-on.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>53 HBeAg-negative NUC-treated patients with CHB were randomised at a 1:1 ratio to receive pegIFN-\u03b1-2a for 48 weeks, or to continue NUC therapy and then followed up for at least 6 months maintaining NUCs. Serum hepatitis B surface antigen (HBsAg) and hepatitis B core\u2010related antigen (HBcrAg) levels as well as peripheral blood NK cell phenotype and function and HBV-specific T cell responses upon in vitro stimulation with overlapping HBV peptides were measured longitudinally before, during and after pegIFN-\u03b1 therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two cohorts of pegIFN-\u03b1 treated patients were identified according to HBsAg decline greater or less than 0.5 log at week 24 post-treatment. PegIFN-\u03b1 add-on did not significantly improve HBV-specific T cell responses during therapy but elicited a significant multispecific and polyfunctional T cell improvement at week 24 post-pegIFN-\u03b1 treatment compared with baseline. This improvement was maximal in patients who had a higher drop in serum HBsAg levels and a lower basal HBcrAg values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PegIFN-\u03b1 treatment can induce greater functional T cell improvement and HBsAg decline in patients with lower baseline HBcrAg levels. Thus, HBcrAg may represent an easily and reliably applicable parameter to select patients who are more likely to achieve better response to pegIFN-\u03b1 add-on to virally suppressed patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2024-332290","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:33:59Z","timestamp":1721622839000},"page":"1737-1748","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["HBcrAg values may predict virological and immunological responses to pegIFN-\u03b1 in NUC-suppressed HBeAg-negative chronic hepatitis B"],"prefix":"10.1136","volume":"73","author":[{"given":"Andrea","family":"Vecchi","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-8502","authenticated-orcid":false,"given":"Marzia","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Tiezzi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3720-9214","authenticated-orcid":false,"given":"Paola","family":"Fisicaro","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Doselli","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Adelina","family":"Gabor","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Penna","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Montali","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Ceccatelli Berti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Reverberi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Montali","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Department of Biology, Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, IRCCS Foundation Maggiore Policlinico Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Sambarino","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, IRCCS Foundation Maggiore Policlinico Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Laccabue","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Facchetti","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, IRCCS Foundation Maggiore Policlinico Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Schivazappa","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Loggi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Coco","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Pisa University Hospital, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-9571","authenticated-orcid":false,"given":"Daniela","family":"Cavallone","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Pisa University Hospital, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rosselli Del Turco","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Massari","sequence":"additional","affiliation":[{"name":"Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pedrazzi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Unit of Neuroscience, Interdepartmental Center of Robust Statistics (Ro.S.A.), University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Missale","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy"},{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Verucchi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia Rossana","family":"Brunetto","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Pisa University Hospital, Pisa, Italy"},{"name":"Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, IRCCS Foundation Maggiore Policlinico Hospital, Milan, Italy"},{"name":"CRC \u201cA. M. and A. Migliavacca\u201d Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy"},{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7630-5180","authenticated-orcid":false,"given":"Carolina","family":"Boni","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy"},{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"2025120600010568000_73.10.1737.1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","volume":"20","author":"Lim","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025120600010568000_73.10.1737.2","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"2025120600010568000_73.10.1737.3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front Immunol"},{"key":"2025120600010568000_73.10.1737.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.019"},{"key":"2025120600010568000_73.10.1737.5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324646"},{"key":"2025120600010568000_73.10.1737.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.07.014"},{"key":"2025120600010568000_73.10.1737.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.032"},{"key":"2025120600010568000_73.10.1737.8","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Garc\u00eda-L\u00f3pez","year":"2021","journal-title":"J Hepatol"},{"key":"2025120600010568000_73.10.1737.9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.13635","article-title":"Treatment of hepatitis B: is there still a role for interferon","volume":"38 Suppl 1","author":"Vigan\u00f2","year":"2018","journal-title":"Liver Int"},{"key":"2025120600010568000_73.10.1737.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.024"},{"key":"2025120600010568000_73.10.1737.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.08.008"},{"key":"2025120600010568000_73.10.1737.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.029"},{"key":"2025120600010568000_73.10.1737.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158297","article-title":"Pegylated interferon \u03b1-2a triggers NK-cell Functionality and specific T-cell responses in patients with chronic HBV infection without HBsAg seroconversion","volume":"11","author":"Bruder Costa","year":"2016","journal-title":"PLoS One"},{"key":"2025120600010568000_73.10.1737.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.032"},{"key":"2025120600010568000_73.10.1737.15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"2025120600010568000_73.10.1737.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.030"},{"key":"2025120600010568000_73.10.1737.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with Genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2025120600010568000_73.10.1737.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.07.016","article-title":"Predictive role of serum HBsAg and HBcrAg Kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon\u2013based therapy","volume":"24","author":"Chuaypen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025120600010568000_73.10.1737.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2019.03.003"},{"key":"2025120600010568000_73.10.1737.20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.16258","article-title":"Incremental value of HBcrAg to classify 1582 HBeAg\u2010negative individuals in chronic infection without liver disease or hepatitis","volume":"53","author":"Brunetto","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120600010568000_73.10.1737.21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"Rnai-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025120600010568000_73.10.1737.22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jhep.2022.03.028","article-title":"The challenges of adopting immunological biomarkers in the management of chronic HBV infection","volume":"77","author":"Bertoletti","year":"2022","journal-title":"J Hepatol"},{"key":"2025120600010568000_73.10.1737.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005788","article-title":"Interferon alpha induces sustained changes in NK cell responsiveness to hepatitis B viral load suppression in vivo","volume":"12","author":"Gill","year":"2016","journal-title":"PLOS Pathog"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2024-332290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T08:01:14Z","timestamp":1765008074000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2024-332290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,9,9]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/gutjnl-2024-332290"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2024-332290","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]}}}